Diligence memo · auto-generated · as of July 2, 2026
Acton Pharmaceuticals, Inc.
Acton Pharmaceuticals, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Acton Pharmaceuticals, Inc. operates in Pharmaceuticals, based in MARLBOROUGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Acton Pharmaceuticals, Inc. has raised $22M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $14M on 2010-09-29.
Most recent recorded round closed around 2013-05-13.
Valuation (modeled)modeled
Provath models Acton Pharmaceuticals, Inc. at approximately $217M (range $8.0M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.10× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era. Within the normal band (110% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 13.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 67% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 70% of those peers.
Closest niche peers: Aquinox Pharmaceuticals (Usa) Inc, Neurovia, Inc., Romark Global Pharma, LLC, Access Pharmaceuticals Inc, Minnesota Medical Solutions LLC.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.